MindMaze Therapeutics Holding S.A. (RLFTF) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

MindMaze Therapeutics Holding S.A. (RLFTF) Healthcare & Pipeline Overview

MindMaze Therapeutics Holding S.A. is a Swiss biotechnology firm leveraging its MindMaze platform to integrate neuroscience and digital therapeutics, targeting significant challenges in neurology. Established in 2025, the company focuses on innovative solutions for brain repair and neurorehabilitation within the evolving healthcare landscape.

What Is the Investment Thesis for RLFTF?

MindMaze Therapeutics Holding S.A. presents an investment thesis centered on its innovative MindMaze platform, which integrates neuroscience and digital therapeutics to address critical neurological challenges. The company's focus on neurorehabilitation and brain repair positions it within a growing market driven by an aging global population and increasing prevalence of neurological disorders. With a gross margin of 92.1%, MindMaze demonstrates strong operational efficiency in its current business model. The demand for advanced neurorehabilitation technologies, particularly digital solutions, is a significant growth catalyst. However, as an OTC-listed company with a market capitalization of $3.35M and a negative ROE of -51.6%, RLFTF carries inherent risks, including significant liquidity and volatility concerns. Future value drivers depend heavily on successful clinical trial outcomes, securing adequate funding for research and development, and achieving regulatory approvals for its digital therapeutic and medical device solutions. Investors must monitor progress in these areas to assess the company's potential for commercialization and market penetration, as well as its ability to mitigate the risks associated with its early-stage development and OTC trading status.

Based on FMP financials and quantitative analysis

RLFTF Key Highlights

Gross Margin of 92.1% indicates strong profitability on revenue, suggesting efficient cost management relative to sales.

• Return on Equity (ROE) of -51.6% reflects significant losses relative to shareholder equity, common for early-stage biotechnology firms.
• Beta of 1.19 suggests the stock is moderately more volatile than the overall market, indicating higher sensitivity to market fluctuations.
• The company operates with 31 employees, indicating a lean organizational structure for a biotechnology firm.
• Established in 2025, MindMaze Therapeutics Holding S.A. is a relatively new entrant in the biotechnology sector, focusing on innovative platform development.

Who Are RLFTF's Competitors?

RLFTF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are RLFTF's Key Strengths?

Innovative MindMaze platform integrating neuroscience and digital therapeutics.

• High gross margin of 92.1% indicates efficient cost management on revenue.
• Focus on the growing market of neurorehabilitation and brain repair.
• Headquartered in Switzerland, a hub for medical innovation.

What Are RLFTF's Weaknesses?

Small market capitalization of $3.35M, indicating limited scale and financial resources.

• Negative Return on Equity (-51.6%) reflects current unprofitability, common for early-stage biotech.
• OTC Other tier listing, which typically implies lower liquidity and transparency.
• Relatively new company, established in 2025, with limited operational history.

What Could Drive RLFTF Stock Higher?

RLFTF catalyst: Positive clinical trial outcomes for the MindMaze platform could validate its efficacy and significantly enhance investor confidence and market potential.

• Successful completion of future funding rounds would provide necessary capital for continued research, development, and potential commercialization efforts.
• Achievement of key regulatory milestones, such as FDA or EMA clearances for its digital therapeutics or medical devices, would enable market entry.
• Enhancements and expansions of the MindMaze platform's capabilities, potentially targeting new neurological indications or improving existing functionalities.

What Are the Key Risks for RLFTF?

Financial-distress signal — its Altman Z-Score of -1.81 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-51.6%) — the business is not currently generating profit on shareholder capital.
• Significant liquidity and volatility risks associated with trading on the OTC Other tier, potentially leading to large price fluctuations and difficulty in trading.
• Failure to secure adequate future funding could impede research and development, as well as delay or halt commercialization efforts.
• Unfavorable clinical trial results or delays in trial progression could negatively impact the perceived efficacy and market viability of the MindMaze platform.
• Challenges in obtaining regulatory approvals for its digital therapeutics and medical devices could delay market entry and revenue generation.
• Intense competition within the neurorehabilitation and digital therapeutics market could limit market share and profitability.

What Are the Growth Opportunities for RLFTF?

• Growing Demand for Neurorehabilitation Technologies: The global prevalence of neurological disorders is increasing, leading to a rising demand for effective neurorehabilitation solutions. Conditions like stroke, traumatic brain injury, and multiple sclerosis necessitate long-term rehabilitation, creating a substantial market. MindMaze Therapeutics, with its digital therapeutic platform, is well-positioned to capitalize on this trend by offering innovative, accessible, and potentially more engaging rehabilitation methods. The market for neurorehabilitation devices and therapies is projected to grow significantly, driven by technological advancements and an aging population, offering a multi-billion dollar opportunity over the next decade.
• Advancements in Digital Therapeutics (DTx): The broader digital therapeutics market is experiencing rapid expansion, with increasing acceptance from healthcare providers and payers. Digital therapeutics offer evidence-based interventions delivered through software programs to prevent, manage, or treat a medical disorder or disease. MindMaze's integration of neuroscience with DTx allows it to develop solutions that can potentially offer personalized, data-driven, and scalable treatments for neurological conditions, reducing healthcare costs and improving patient access. This segment is expected to see double-digit annual growth rates, representing a significant avenue for MindMaze's expansion.
• Expansion into New Neurological Conditions: While the company's current focus is on general neurology and brain repair, the MindMaze platform's underlying technology could be adapted for a wider range of neurological and psychiatric conditions. This includes potential applications in conditions such as Parkinson's disease, Alzheimer's disease, or even mental health disorders where neurocognitive training and digital interventions can play a therapeutic role. Diversifying its therapeutic indications could unlock new market segments and revenue streams, significantly broadening its total addressable market beyond its initial scope, with development timelines extending over several years.
• Strategic Partnerships and Collaborations: Forming strategic alliances with pharmaceutical companies, research institutions, and healthcare providers can accelerate MindMaze's product development, clinical validation, and market penetration. Collaborations can provide access to specialized expertise, funding, and established distribution channels, particularly in a capital-intensive sector like biotechnology. Partnerships could also facilitate the integration of the MindMaze platform into existing healthcare ecosystems, enhancing its reach and adoption. Such alliances could range from co-development agreements to commercialization partnerships, potentially materializing within the next 2-3 years.
• Clinical Trial Success and Product Commercialization: The successful completion of clinical trials and subsequent regulatory approvals are paramount for any biotechnology company. Positive outcomes from ongoing or upcoming clinical trials for the MindMaze platform would significantly de-risk the company's profile and pave the way for commercialization. Achieving regulatory clearances (e.g., FDA, EMA) for its digital therapeutics and medical devices would enable MindMaze to generate revenue through product sales or licensing agreements. The successful launch and market adoption of its initial products would be a critical growth driver, with commercialization timelines typically spanning several years post-approval.

What Threats Does RLFTF Face?

• Significant liquidity and volatility risks associated with OTC trading.
• Intense competition from established medical device companies and emerging digital health startups.
• High regulatory hurdles and lengthy approval processes for medical devices and therapeutics.
• Dependence on successful clinical trial outcomes and securing future funding rounds.
• Risk of market acceptance and adoption challenges for new digital therapeutic solutions.

What Are RLFTF's Competitive Advantages?

• Proprietary MindMaze platform integrating neuroscience and digital therapeutics, offering a specialized approach.
• Potential for intellectual property protection around its unique digital therapeutic algorithms and medical device designs.
• Early mover advantage in specific niches of digital neurorehabilitation, building expertise and clinical data.
• Interdisciplinary approach combining deep neuroscience understanding with advanced digital technology development.

What Does RLFTF Do?

MindMaze Therapeutics Holding S.A., formerly known as NeuroX Group S.A., is a pioneering biotechnology company headquartered in Lausanne, Switzerland, established in 2025. The company's core mission revolves around the creation and operation of its proprietary MindMaze platform, which represents a significant advancement at the intersection of neuroscience and digital therapeutics. This innovative platform is specifically designed to address some of the most complex and pressing challenges within the field of neurology, focusing on rehabilitation and recovery following neurological injuries. By integrating advanced neuroscience principles with cutting-edge digital therapeutic interventions, MindMaze aims to provide solutions that enhance brain repair and functional restoration. The company's approach involves developing medical devices and software-based therapies that leverage immersive technologies, real-time feedback, and personalized treatment protocols to optimize patient outcomes. MindMaze Therapeutics operates within the rapidly expanding global market for neurorehabilitation technologies, where there is a growing demand for effective, evidence-based interventions that can improve the quality of life for individuals affected by neurological conditions. Its strategic positioning in Switzerland, a hub for medical innovation, supports its focus on high-quality research and development. The company's relatively recent establishment in 2025 indicates a modern, forward-looking approach to healthcare, aiming to disrupt traditional rehabilitation methods with digitally-enabled, patient-centric solutions. MindMaze's commitment to tackling significant neurological challenges through its integrated platform underscores its ambition to become a key player in the future of neurotherapeutics.

What Products and Services Does RLFTF Offer?

• Develop and operate the MindMaze platform, integrating neuroscience and digital therapeutics.
• Focus on addressing significant challenges within the field of neurology.
• Create solutions for brain repair and recovery after neurological injuries.
• Utilize digital therapeutics, which are evidence-based software programs for medical conditions.
• Develop medical devices aimed at neurorehabilitation.
• Headquartered in Lausanne, Switzerland, and established in 2025.

How Does RLFTF Make Money?

• Develop and potentially license its proprietary MindMaze platform and associated digital therapeutic solutions.
• Generate revenue through the sale or subscription of its medical devices and digital therapeutics to healthcare providers and patients.
• Potentially engage in strategic partnerships for co-development or commercialization of its neurotherapeutic products.
• Focus on research and development to innovate and expand its product pipeline within neurology.

What Industry Does RLFTF Operate In?

MindMaze Therapeutics Holding S.A. operates within the dynamic and rapidly evolving Biotechnology industry, specifically targeting the neurotherapeutics and digital health segments of the broader Healthcare sector. The industry is characterized by significant research and development investments, stringent regulatory pathways, and a high potential for innovation in addressing unmet medical needs. MindMaze's focus on integrating neuroscience with digital therapeutics positions it at the forefront of a growing trend towards technology-enabled healthcare solutions. The global neurorehabilitation market, which includes digital therapeutics for neurological conditions, is projected to experience substantial growth driven by an aging population, increasing incidence of neurological disorders such as stroke, Parkinson's disease, and traumatic brain injury, and advancements in medical technology. While the competitive landscape includes established pharmaceutical companies, medical device manufacturers, and emerging digital health startups, MindMaze aims to differentiate itself through its specialized MindMaze platform. The company's success will depend on its ability to navigate regulatory challenges, secure intellectual property, and demonstrate clinical efficacy in a highly competitive environment.

Who Are RLFTF's Key Customers?

• Patients undergoing neurorehabilitation for various neurological injuries and conditions.
• Healthcare providers, including neurologists, rehabilitation specialists, and therapists.
• Rehabilitation centers, hospitals, and clinics seeking advanced neurotherapeutic tools.
• Potentially pharmaceutical companies for co-development or licensing opportunities related to neurological disorders.

Wall Street analysts project MindMaze Therapeutics Holding S.A. revenue of about $4.7M for fiscal 2026, with EPS near $0.00.

MindMaze Therapeutics Holding S.A.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -1.81 places it in the distress zone, a signal of elevated financial risk.

Return on equity for MindMaze Therapeutics Holding S.A. stands at -51.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -25.5%, showing how much profit it generates from its asset base. RLFTF trades at a trailing price-to-earnings ratio of 0.00, below the Healthcare sector average of ~23x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.20 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.

MindMaze Therapeutics Holding S.A. (RLFTF) Valuation Context

Valued at $3.35M, RLFTF is classified as a micro-cap stock. Relative to its peer group, RLFTF's quantitative score of 55/100 is below the peer average of 76/100.

RLFTF Revenue & Earnings Trend

In Q4 2025, RLFTF generated $-576K in top-line revenue, marking a sequential decrease of 147.3%. The company recorded a net loss of $5.4M, with diluted EPS of $-0.26. Revenue has contracted over three consecutive quarters, which investors in this micro-cap Healthcare stock should monitor closely. Across the four most recent quarters, RLFTF averaged $-0.50 in diluted EPS.

Company Profile

MindMaze Therapeutics Holding S.A. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Geneva, CH. The company is led by CEO Zach Henderson. RLFTF has traded publicly since 2021.

RLFTF Financials

RLFTF Latest News

RLFTF Analyst Consensus

RLFTF MoonshotScore

RLFTF Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources